European Multiple Myeloma Patients Face Unequal Access to Curative Treatments
By
Cristina Ferrario
Summary
At the European Hematology Association (EHA) 2026 Congress in Stockholm, speakers highlighted that while new drugs and treatment combinations make cure a realistic goal for many multiple myeloma (MM) patients in Europe, significant disparities in access to these treatments persist. These inequities are driven not by patient or disease characteristics but by differences in drug availability and access across European countries. Patient advocates and clinicians discussed how these inequalities compromise survival outcomes and explored solutions to address the access gap.
Source
Twitter / XEuropean Multiple Myeloma Patients Face Unequal Access to Curative Treatmentsmdsc.peKey quotes
· 3 pulledNew drugs and treatment combinations make cure a realistic therapeutic goal for many — but not all — patients with multiple myeloma (MM) in Europe.
The reasons for these discrepancies extend beyond patient- and disease-related characteristics, often building on inequities in drug access and availability across European countries.
Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.
You might also wanna read
Unequal Access to New Myasthenia Gravis Therapies Across Europe Highlights Healthcare Disparities
This article examines the growing gap between medical innovation and patient access in the treatment of generalised myasthenia gravis (gMG)
euractiv.com·6d ago
Australia's slow progress on equitable cancer prostheses access harms rural patients, analyst warns
Health policy analyst Charles Maskell-Knight reports that efforts to ensure equitable access to prostheses for cancer patients in Australia
croakey.org·19d ago
Five EU countries seek unified response to US and pharma pressure on drug pricing
Five EU countries are calling for a united European response to pressure from the U.S. and pharmaceutical companies demanding higher drug pr
politico.eu·20d ago
EU healthcare procurement reform should prioritize quality over price-only bidding, not just buying European
The article argues that Europe's healthcare resilience depends less on buying European products and more on reforming procurement practices.
dlvr.it·1mo ago
China's biotech rise: A case study in multiple myeloma drug development
This article examines China's rapid advancement in biotechnology through the lens of a multiple myeloma drug development case study. It disc
writingruxandrabio.com·8d ago
Modelling Study Projects Rapid Growth in Radioligand Therapy Patient Populations Across EU and UK Healthcare Systems
This modelling study estimates the future patient populations eligible for radioligand therapies (RLTs) across EU-27 member states and the U
Comments
Sign in to join the conversation.
No comments yet. Be the first.